Tiziana Life Sciences Ltd. Common Shares (TLSA) Stock Price

TLSAStock
$1.05−48.02%52W
Market Cap$133.62M
P/E—
PEG Ratio—
Div yield—
Beta0.40

TLSA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-28.51%
Price vs S&P 500 (4W)17.40%
VGM Score55.15

TLSA Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
TLSATiziana Life Sciences Ltd. Common Shares
——C————$1.05
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Tiziana Life Sciences Ltd. Common Shares

Tiziana Life Sciences is a clinical-stage biotechnology company developing immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's lead candidate, Foralumab (a fully human anti-CD3 monoclonal antibody), is in development for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's disease, and other CNS indications. Its pipeline also includes programs for ALS.